Marinomed Biotech AG
VSE:MARI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Marinomed Biotech AG
Depreciation & Amortization
Marinomed Biotech AG
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Marinomed Biotech AG
VSE:MARI
|
Depreciation & Amortization
-€1.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Marinomed Biotech AG
Glance View
Marinomed Biotech AG is a biopharmaceutical company, which engages in the development of therapies based on patent protected technology platforms. The company is headquartered in Korneuburg, Niederoesterreich and currently employs 43 full-time employees. The company went IPO on 2019-02-01. The firm develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The firm also offers products for the treatment of influenza, combination products for asthmatics, and others. The firm also develops treatments for type I allergies and autoimmune diseases. The firm is a spin-off from the University of Veterinary Medicine, Vienna.
See Also
What is Marinomed Biotech AG's Depreciation & Amortization?
Depreciation & Amortization
-1.2m
EUR
Based on the financial report for Jun 30, 2025, Marinomed Biotech AG's Depreciation & Amortization amounts to -1.2m EUR.
What is Marinomed Biotech AG's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-27%
Over the last year, the Depreciation & Amortization growth was -85%. The average annual Depreciation & Amortization growth rates for Marinomed Biotech AG have been -23% over the past three years , -27% over the past five years .
